Increased levels of immune transcript in patients with acute GVHD after allogeneic stem cell transplantation

被引:15
作者
Jaksch, M [1 ]
Uzunel, M
Cangana, GM
Remberger, M
Mattsson, J
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Div Clin Immunol, SE-14186 Stockholm, Sweden
[2] Huddinge Univ Hosp, Karolinska Inst, CAST, Stockholm, Sweden
关键词
GVHD; SCT; quantitative RT-PCR;
D O I
10.1038/sj.bmt.1703807
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
After allogeneic stem cell transplantation (SCT), donor T-cells are primarily responsible for the antihost activity, resulting in graft-versus-host disease (GVHD). Three effector pathways have been described for T-cell cytotoxicity: perforin/granzyme B; Fas/Fas ligand (FasL) and secreted molecules such as TNIT-alpha. The goal of this pilot study was to utilize competitive reverse transcription (RT)PCR to evaluate the pattern of granzyme B, perforin, FasL and TNF-alpha gene expression in peripheral blood in patients after SCT. Protein levels of granzyme B, soluble FasL (sFasL) and TNF-alpha in plasma were also analyzed. Eight patients who underwent allogeneic SCT were included; five were diagnosed with acute GVHD. In the patients diagnosed with acute GVHD, we found increased levels of granzyme B, perforin and FasL mRNA, although this did not correlate with the clinical severity. However, patients with increasing levels of gene expression during acute GVHD treatment may have an increased risk of developing severe acute GVHD, as two out of three patients with increasing immune transcript levels during GVHD therapy developed life-threatening acute GVHD. In conclusion, the quantitative RT-PCR of granzyme B, perforin and FasL may serve as a guide to the clinician in diagnosing acute GVHD and monitoring treatment.
引用
收藏
页码:183 / 190
页数:8
相关论文
共 38 条
[21]   THE FAS DEATH FACTOR [J].
NAGATA, S ;
GOLSTEIN, P .
SCIENCE, 1995, 267 (5203) :1449-1456
[22]  
REMBERGER M, 1995, BONE MARROW TRANSPL, V15, P99
[23]   Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation [J].
Remberger, M ;
Svahn, BM ;
Hentschke, P ;
Löfgren, C ;
Ringdén, O .
BONE MARROW TRANSPLANTATION, 1999, 24 (08) :823-830
[24]  
Remberger M, 1997, EUR J HAEMATOL, V59, P254
[25]   Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors [J].
Remberger, M ;
Storer, B ;
Ringdén, O ;
Anasetti, C .
BONE MARROW TRANSPLANTATION, 2002, 29 (05) :391-397
[26]   Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including, anti-T-cell antibodies [J].
Ringdén, O ;
Remberger, M ;
Carlens, S ;
Hagglund, H ;
Mattsson, J ;
Aschan, J ;
Lönnqvist, B ;
Klaesson, S ;
Winiarski, J ;
Dalianis, T ;
Olerup, O ;
Sparrelid, E ;
Elmhorn-Rosenborg, A ;
Svahn, BM ;
Ljungman, P .
TRANSPLANTATION, 1998, 66 (05) :620-625
[27]   Peripheral blood stem cell transplantation from unrelated donors:: A comparison with marrow transplantation [J].
Ringdén, O ;
Remberger, M ;
Runde, V ;
Bornhäuser, M ;
Blau, IW ;
Basara, N ;
Hölig, K ;
Beelen, DW ;
Hägglund, H ;
Basu, O ;
Ehninger, G ;
Fauser, AA .
BLOOD, 1999, 94 (02) :455-464
[28]  
RINGDEN O, 1995, BONE MARROW TRANSPL, V15, P619
[29]   A RANDOMIZED TRIAL COMPARING BUSULFAN WITH TOTAL-BODY IRRADIATION AS CONDITIONING IN ALLOGENEIC MARROW TRANSPLANT RECIPIENTS WITH LEUKEMIA - A REPORT FROM THE NORDIC-BONE-MARROW-TRANSPLANTATION-GROUP [J].
RINGDEN, O ;
RUUTU, T ;
REMBERGER, M ;
NIKOSKELAINEN, J ;
VOLIN, L ;
VINDELOV, L ;
PARKKALI, T ;
LENHOFF, S ;
SALLERFORS, B ;
LJUNGMAN, P ;
MELLANDER, L ;
JACOBSEN, N .
BLOOD, 1994, 83 (09) :2723-2730
[30]  
Ringden O DH, 1996, GRAFT VS HOST DIS, P525